U.S. FDA and NIH Back Smoking Cessation Innovation, Highlight E-Cigarette Research Needs

Oct.16.2024
U.S. FDA and NIH Back Smoking Cessation Innovation, Highlight E-Cigarette Research Needs
FDA and NIH leaders emphasize the need for smoking cessation treatment research and innovation in a new commentary.

According to a news release posted on the official website of the U.S. Food and Drug Administration (FDA) on October 15, leaders from the National Institutes of Health (NIH) and FDA emphasized the importance of advancing research and development for smoking cessation treatments in a new commentary published in the Annals of Internal Medicine. The authors of the article updated regulatory pathways for smoking cessation treatments and outlined innovative treatment targets, research gaps, and development opportunities. They stressed the crucial role of active participation from clinical physicians, academia, industry, public health agencies, patient groups, and other stakeholders.


Data shows that nearly 500,000 people die from smoking in the United States each year, with over 28 million adults smoking in the country. While most smokers express a desire to quit, only 31% of those intending to quit actually seek counseling or medication treatment. The success rate for quitting smoking each year is less than 8%.


The commentator proposed solutions to these issues, including recommendations from the FDA 2023 Nicotine Replacement Therapy guidelines. In order to inspire innovation in smoking cessation product development, the commentator suggested that in smoking cessation trials, in addition to focusing on abstinence, meaningful endpoints should also be considered, such as clinically significant reduction in smoking, especially if this reduction increases the likelihood of eventual cessation.


The authors also emphasized the urgent need for more in-depth research on e-cigarettes, including long-term health outcomes and rigorous toxicology studies. They also discussed programs being conducted by the NIH and FDA aimed at promoting innovative research on smoking cessation, particularly targeting underrepresented groups in historical research trials.


This commentary was released prior to the joint public meeting of the FDA and NIH on advancing smoking cessation priorities, which is scheduled to take place on October 21 from 9:00 AM to 4:30 PM (Eastern Time).


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Australia Leads COP11 Seminars as Exploding Illicit Tobacco Market Raises Questions
Australia Leads COP11 Seminars as Exploding Illicit Tobacco Market Raises Questions
Australia sent a delegation to COP11 in Switzerland and is leading three major seminars to showcase its vape and tobacco control policies. But at home, illicit cigarette sales are skyrocketing amid record-high taxes, drawing criticism from the tobacco industry and prompting doubts over policy effectiveness.
Nov.20 by 2FIRSTS.ai
Product | FLONQ Parent Company Launches New Vaping Brand ROQY: Two Hybrid-Nicotine Devices Debut in Russia
Product | FLONQ Parent Company Launches New Vaping Brand ROQY: Two Hybrid-Nicotine Devices Debut in Russia
Alfabet Labs, the parent company of FLONQ, has recently launched its new vaping brand ROQY in Russia, debuting two products: ROQY L and ROQY M. Both devices use a hybrid nicotine formulation combining nicotine salts and freebase nicotine and are each available in 19 flavors. The two products are now on sale via the official ROQY website as well as multiple online and offline retailers across Russia.
Nov.19 by 2FIRSTS.ai
2Firsts Monitor | FOGER website flags customs & tariff delays; some products out of stock
2Firsts Monitor | FOGER website flags customs & tariff delays; some products out of stock
2Firsts observed on FOGER’s online retail site “FOGER VAPES” that the platform indicates restocking delays due to customs and tariff factors. Several items show limited availability or “sold out” status, with a restock alert feature offered. A previous article on the site also referenced potential tariff changes that may affect pricing.
Nov.05
Product | NEXA FLEX Releases “Built in the USA” Version, Says All Flavors Are Tailored for Adult U.S. Users
Product | NEXA FLEX Releases “Built in the USA” Version, Says All Flavors Are Tailored for Adult U.S. Users
NEXA has introduced a disposable e-cigarette, NEXA FLEX, which is promoted as “Built in the USA,” highlighting domestic production and flavors developed for adult U.S. vaping consumers. The device retains features such as a transparent e-liquid chamber, Normal/Turbo dual modes, and up to 40,000 puffs, and is scheduled to launch in late November in Texas. Other brands, including SKE and FASTA, have also recently released products labeled as “Made in the USA” or “U.S.-assembled.”
Nov.20 by 2FIRSTS.ai
Co-op Faces Backlash Over Vape Promotion Strategy Post-Cyberattack
Co-op Faces Backlash Over Vape Promotion Strategy Post-Cyberattack
The Guardian reports that UK retailer Co-op is ramping up vape promotions to recover sales lost after an April cyberattack. Internal documents cite a £1M weekly sales gap and 100,000 fewer transactions. Staff say the move contradicts Co-op’s “ethical retail” image, as the government prepares to ban vape ads under the Tobacco and Vapes Bill.
Oct.28 by 2FIRSTS.ai
Ukraine intensifies crackdown on illicit tobacco and alcohol markets
Ukraine intensifies crackdown on illicit tobacco and alcohol markets
Ukraine’s State Tax Service (GNS) has carried out around 24,000 on-site inspections in the tobacco and alcohol sectors this year, imposing more than ₴795 million (US$194 million) in fines and revoking over 2,500 business licences.
Oct.17 by 2FIRSTS.ai